It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ERAS’s FA Score shows that 1 FA rating(s) are green whileORIC’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ERAS’s TA Score shows that 7 TA indicator(s) are bullish while ORIC’s TA Score has 3 bullish TA indicator(s).
ERAS (@Biotechnology) experienced а +5.87% price change this week, while ORIC (@Biotechnology) price change was -7.16% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.
ERAS is expected to report earnings on Nov 06, 2024.
ORIC is expected to report earnings on Nov 04, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ERAS | ORIC | ERAS / ORIC | |
Capitalization | 808M | 681M | 119% |
EBITDA | -148.65M | -124.06M | 120% |
Gain YTD | 39.671 | 2.935 | 1,352% |
P/E Ratio | N/A | N/A | - |
Revenue | 0 | 0 | - |
Total Cash | 408M | 286M | 143% |
Total Debt | 54M | 2.77M | 1,949% |
ERAS | ORIC | |
---|---|---|
RSI ODDS (%) | 3 days ago87% | N/A |
Stochastic ODDS (%) | 3 days ago81% | 3 days ago90% |
Momentum ODDS (%) | 3 days ago83% | 3 days ago86% |
MACD ODDS (%) | 3 days ago88% | 3 days ago90% |
TrendWeek ODDS (%) | 3 days ago80% | 3 days ago87% |
TrendMonth ODDS (%) | 3 days ago77% | 3 days ago81% |
Advances ODDS (%) | 3 days ago78% | 9 days ago84% |
Declines ODDS (%) | about 1 month ago86% | 3 days ago87% |
BollingerBands ODDS (%) | 3 days ago90% | 3 days ago86% |
Aroon ODDS (%) | 3 days ago83% | 3 days ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
AINTX | 15.48 | 0.08 | +0.52% |
Ariel International Investor | |||
PIIFX | 27.43 | 0.11 | +0.40% |
Pioneer International Equity A | |||
VFSNX | 230.50 | 0.66 | +0.29% |
Vanguard FTSE All-Wld ex-US SmCp Idx Ins | |||
ACWDX | 16.82 | N/A | N/A |
AMG GW&K Small/Mid Cap Growth N | |||
BHEIX | 29.30 | -0.12 | -0.41% |
BlackRock High Equity Income K |
A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.
Ticker / NAME | Correlation To ERAS | 1D Price Change % | ||
---|---|---|---|---|
ERAS | 100% | +6.63% | ||
XNCR - ERAS | 50% Loosely correlated | -1.86% | ||
KYMR - ERAS | 44% Loosely correlated | +0.93% | ||
ABOS - ERAS | 43% Loosely correlated | -5.00% | ||
BEAM - ERAS | 42% Loosely correlated | +0.46% | ||
ABCL - ERAS | 42% Loosely correlated | -3.57% | ||
More |
A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with SVRA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then SVRA could also see price increases.
Ticker / NAME | Correlation To ORIC | 1D Price Change % | ||
---|---|---|---|---|
ORIC | 100% | -1.25% | ||
SVRA - ORIC | 42% Loosely correlated | +2.95% | ||
FULC - ORIC | 42% Loosely correlated | +4.73% | ||
KYMR - ORIC | 42% Loosely correlated | +0.93% | ||
DAWN - ORIC | 41% Loosely correlated | +4.39% | ||
ACLX - ORIC | 41% Loosely correlated | +7.50% | ||
More |